tiprankstipranks
Market News

CRSP Stock Misses Earnings; Here’s Why Revenue Plunged

Story Highlights

CRSP is a speculative stock with a heavy cash burn. Despite this and its earnings miss, investors still have a favorable view of the stock.

CRISPR Therapeutics (CRSP) recently reported earnings for its second quarter of Fiscal Year 2022. CRSP’s Adjusted earnings per share came in at -$2.40, which missed analysts’ consensus estimate of -$2.22. In addition, sales fell over 99% year-over-year, with revenue hitting $158,000 compared to $900.7 million. This massive difference is the result of a $900 million upfront payment in Q2 2021 from Vertex for a Joint Development and Commercialization Agreement.

As a result, shares have been trading lower since the report. In the past eight quarters, the company has beat estimates two times. Furthermore, CRSP had free cash flow of -$151.6 million. With such a heavy cash burn, the company needs a balance sheet with a sufficient cash position to sustain it. Fortunately, CRSP has $1.37 billion in cash, cash equivalents, and short-term investments.

Investor Sentiment For CRSP Stock is Neutral

The sentiment among TipRanks investors is currently neutral. Out of the 552,359 portfolios tracked by TipRanks, 1.3% hold CRSP. In addition, the average portfolio weighting allocated towards CRSP among those who do have a position is 4.15%. This suggests that investors of the company are quite confident about its future.

Indeed, in the last 30 days, 0.4% of those holding the stock increased their positions. As a result, the stock’s sentiment is slightly above the sector average, as demonstrated in the following image:

Is CRSP Stock a Good Buy?

CRSP has a Moderate Buy consensus rating based on 10 Buys and seven Holds assigned in the past three months. The average CRSP price target of $100.44 implies 29.1% upside potential.

Top Analyst Gena Wang from Barclays was pleased that regulatory submissions for gene editing candidates were on track. Nevertheless, she downgraded the stock to a Hold and cut the price target to $88 per share due to the lack of data catalysts in the next 12 months.

Takeaway – CRSP Stock is Speculative, but Investors Remain Positive

CRSP is still a cash-burning company and isn’t expected to be profitable anytime soon, which makes it a speculative bet. Nevertheless, both analysts and investors have a favorable view of the company as they believe that it has a promising future in the long run.

Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More